Biotie Agrees to Acquire Newron to Strengthen its Late-Stage CNS Pipeline
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 10 (Table of Contents)
Published: 10 Oct-2011
DOI: 10.3833/pdr.v2011.i10.1570 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In order to strengthen its CNS pipeline and create critical mass, Biotie Therapies has agreed to acquire Italian Newron Pharmaceuticals in an all-stock deal that is valued at €45 M (US$61 M), including Contingent Value Rights...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS